XLO
Xilio Therapeutics Inc

1,565
Mkt Cap
$49.36M
Volume
58,469.00
52W High
$16.10
52W Low
$6.47
PE Ratio
-2.26
XLO Fundamentals
Price
$8.25
Prev Close
$8.58
Open
$8.40
50D MA
$8.19
Beta
0.78
Avg. Volume
31,579.21
EPS (Annual)
-$4.19
P/B
0.66
Rev/Employee
$575,868.42
$55.66
Loading...
Loading...
News
all
press releases
Cancer Stocks That Are Advancing the Future of Oncology Care
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
News Placeholder
More News
News Placeholder
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Xilio Therapeutics (XLO) delivered earnings and revenue surprises of +12.12% and +48.45%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Oculis Holding AG (OCS) delivered earnings and revenue surprises of -27.71% and -17.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
News Placeholder
Wall Street Zen Upgrades Xilio Therapeutics (NASDAQ:XLO) to Buy
Wall Street Zen raised Xilio Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday...
News Placeholder
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.
News Placeholder
Xilio Therapeutics (NASDAQ:XLO) Shares Down 4.8% - What's Next?
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 4.8% - What's Next...
News Placeholder
Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading Volume - Here's What Happened
Xilio Therapeutics (NASDAQ:XLO) Sees Strong Trading Volume - Here's Why...
News Placeholder
Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates
Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 0.00% and -28.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available